key: cord-0015065-4ka9t9ie
authors: Bafna, Khushboo; Krug, Robert M.; Montelione, Gaetano T.
title: Structural Similarity of SARS-CoV2 M(pro) and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics
date: 2020-04-21
journal: ChemRxiv
DOI: 10.26434/chemrxiv.12153615
sha: ab8324e7ce2f32027b9d21275059d122d6d519b9
doc_id: 15065
cord_uid: 4ka9t9ie

During the current COVID-19 pandemic more than 160,000 people have died worldwide as of mid-April 2020, and the global economy has been crippled. Effective control of the SARS-CoV2 virus that causes the COVID-19 pandemic requires both vaccines and antivirals. Antivirals are particularly crucial to treat infected people during the period of time that an effective vaccine is being developed and deployed. Because the development of specific antiviral drugs can take a considerable length of time, an important approach is to identify existing drugs already approved for use in humans which could be repurposed as COVID-19 therapeutics. Here we focus on antivirals directed against the SARS-CoV2 M(pro) protease, which is required for virus replication. A structural similarity search showed that the Hepatitis C virus (HCV) NS3/4A protease has a striking three-dimensional structural similarity to the SARS-CoV2 M(pro) protease, particularly in the arrangement of key active site residues. We used virtual docking predictions to assess the hypothesis that existing drugs already approved for human use or clinical testing that are directed at the HCV NS3/4A protease might fit well into the active-site cleft of the SARS-CoV2 protease (M(pro)). AutoDock docking scores for 12 HCV protease inhibitors and 9 HIV-1 protease inhibitors were determined and compared to the docking scores for an α-ketoamide inhibitor of M(pro), which has recently been shown to inhibit SARS-CoV2 virus replication in cell culture. We identified eight HCV protease inhibitors that bound to the M(pro) active site with higher docking scores than the α-ketoamide inhibitor, suggesting that these protease inhibitors may effectively bind to the M(pro) active site. These results provide the rationale for us to test the identified HCV protease inhibitors as inhibitors of the SARS-CoV2 protease, and as inhibitors of SARS-CoV2 virus replication. Subsequently these repurposed drugs could be evaluated as COVID-19 therapeutics.

conformation ( Figure 4B ). Comparative analysis of the docked inhibitor with the crystal 1 structure pose shows that all of the key protein ligand interactions are reproduced. In 2 this pose, the amide oxygen of inhibitor 13b forms hydrogen bonds with the backbone N 3 atoms of Gly143, Ser144 and Cys145, which form the canonical "oxyanion hole" of the 4 cysteine protease (13). As in the crystal structure of the complex, sidechain N ε of His41 5 stabilizes the hydroxyl group of the thiohemiketal by forming a hydrogen bond. In 6 addition, the Cys143 S g -inhibitor C distance of 2.3 Å is close to that of the X-ray crystal 7 structure, 1.8 Å, where a "reversible" thiohemiketal covalent bond is formed between the 8 protein and this C atom of 13b. Residues Phe140 (carbonyl O), His163 (N ε ) and Glu166 9 (sidechain carboxylic O and backbone N) also form hydrogen bonds with the inhibitor in 10 the S1 pocket. Hydrophobic interactions with Pro168 and Gln189 sidechains observed 11

in the X-ray crystal structure are also reproduced. The AutoDock binding energy for this 12 binding mode is -7.19 kcal/mol (Table 1 ). This value reflects the non-covalent 13 energetics of the ligand conformation and the ligand-protein interactions in this pose 14 within the active site. It is a useful guide for comparative analysis of relative binding 15 energies for other ligands in our study. However, this binding energy does not include 16 covalent bond energies that may result from formation of the "reversible" thiohemiketal 17

S--C bond, which may contribute to further stabilization of the complex observed in the 18 crystal structure. 19 20 Next we calculated the binding of inhibitor 13b to M pro allowing dihedral bond 21 rotations, as was done in the docking simulations of the other ligands (described below). 22

The best scoring docked conformation of 13b ( Figure 4C ) has an AutoDock binding 23 energy of -9.17 kcal/mol, much lower than the crystal structure conformation. Although 24 the bound conformation of the inhibitor is now significantly different from its 25 conformation in the crystal structure, key ligand-protein interactions are reproduced. 1

The sidechain of catalytic residue His41 (N ε ) again forms a hydrogen bond with the 2 hydroxyl group of the thiohemiketal. The backbone N atoms of Gly143 and Cys145 of 3 the oxyanion hole also again form hydrogen bonds with the amide oxygen of inhibitor 4

13b. The hydrophobic interactions with the sidechain of Met165 are also reproduced. 5

However, in this lower-energy pose, the short S g -C distance consistent with formation 6 of the thiohemiketal covalent bond, is no longer observed. The distance between the 7 thiol S g of Cys145 and α-keto C atom of the inhibitor is 3.5 Å, compared to 1.8 Å in the 8 crystal structure. In the crystal structure, sidechain carboxylic O atom of Glu166 forms a 9

hydrogen bond with the P1 moiety. Due to the flip in conformation of the P1 and P1' 10 groups of inhibitor 13b (labeled in Fig. 4) , Glu166 now interacts with P1' moiety 11

hydrophobically. His41, His164 and Phe181 also form other hydrophobic interactions 12 with the inhibitor that were not observed in the crystal structure. This analysis of the 13 lowest energy AutoDock pose with the crystal structure shows that the AutoDock 14 protocol used in this study is able to reproduce key interactions of the known inhibitor. It 15 appears, however, that in the absence of the S g --C covalent bond between the ligand 16 and the protein, the most preferred docking mode is somewhat different from the 17 docking mode observed in the crystal structure. 18

We also assessed other low energy poses that have fewer differences from the 20 pose observed in the crystal structure that are included among these low energy flexible 21 docking poses. One such pose is shown in Figure 4C . Here, most of the key 22

interactions observed in the crystal structure are preserved, including a short S g -C 23

interatomic distance between catalytic residue Cys143 and the ligand of 3.0 Å. The 24

AutoDock binding energy of this pose is -9.03 kcal/mol (Table 1) , only slightly higher in 25 energy than the lowest energy binding pose described above. Hence, binding poses 1 very similar to that observed in the crystal structure are indeed included among the low 2 energy poses generated by AutoDock, even without inclusion of the energetics of 3 covalent bond formation. 4 5 Docking simulations with HCV NS3/4a protease inhibitors 6

Having validated the use of AutoDock for this system, docking simulation 7 calculations were used to predict bound-state poses for several HCV NS3/4A protease 8 inhibitor drugs. These molecules were compiled from public databases ( Table 1 ). All of 9 these drugs have been approved for at least Phase 1 clinical trials; some are FDA 10 approved prescription drugs useful in treating HepC. AutoDock inhibitor-docking 11 calculations were carried out for each ligand, using the same protocol tested with α-12 ketoamide inhibitor 13b. 13

The AutoDock score of the best scoring pose (i.e., lowest AutoDock binding 15 energy) for each of 12 HCV NSP3/4A protease inhibitors are summarized in Table 1 . 16

These are compared with the AutoDock score of the X-ray crystal structure PDB id 17 6Y2G, the complex of SARS-CoV2 M pro with α-ketoamide inhibitor 13b, and with 13b 18 poses generated with the same docking protocols used for docking these drugs. Eight 19 of the 12 molecules studied have more favorable binding scores than the α-ketoamide 20 inhibitor 13b: AutoDock score -7.19 kcal/mol for crystal structure, and -9.17 kcal/mol for 21 best scoring pose. For these 8 inhibitors the bound-state pose with best AutoDock score 22 also fits well in the active site of SARS-CoV2 M pro , and recapitulates many of the key 23

ligand-protein interactions observed in the complex with α-ketoamide inhibitor 13b. The lowest energy poses for each of the eight best scoring ligands are each 1 compared to that of the X-ray crystal structure of the α-ketoamide inhibitor 13b bound to 2 SARS-CoV2 M pro protease in Figure 5 -8, and details of intermolecular interactions are 3 also shown. A summary of key intermolecular contacts between the inhibitor and M pro 4 in the "lowest energy" poses, for each complex, are presented in Table 2 . In this 5 analysis, we paid particular attention to key details of the "lowest energy" pose, 6

including interactions with the sidechains of catalytic dyad residues His41 and Cys145, 7

and hydrogen-bonded interactions with the backbone amides of Gly143, Ser144 and 8

Cys145, which form the oxyanion hole of this cysteine protease (13). As far as we are 9

aware, none of these drugs form covalent complexes with M pro . Some relevant details 10 about non-covalent ligand-protein interactions in the "lowest energy" poses obtained for 11 each of the 8 top-scoring drugs are outlined in the following paragraphs. SARS-CoV2 with the HCV drugs described above, we also carried out AutoDock 22

docking simulation calculations to predict and rank bound-state poses for nine of these 23 AIDS drugs. These HIV-1 inhibitors were compiled from public databases (Table 3) . 24

Most of these drugs are (or have been) in clinical use as therapeutics for AIDS. 25

AutoDock inhibitor-docking calculations were carried out for each ligand, using the 1 same protocol tested with the α-ketoamide inhibitor 13b and HCV NS3/4A protease 2 inhibitors. For these simulations, 10 docking trajectories were carried out for each drug. 3

The AutoDock scores of the best scoring poses (lowest binding energy), for each of 9 4

HIV-1 protease inhibitors are summarized in Table 3 . The AutoDock binding energy 5 scores for these molecules, ranging from -8.38 to -6.58 kcal/mol, were generally lower-6 ranking than those of the best scoring HCV inhibitors (cf. Tables 1 and 3 ). Nonetheless, 7 some of these complexes have reasonable stability, and we cannot exclude the 8 potential of using these HIV-1 protease inhibitors as therapeutics for COVID-19. reducing the need for hospitalization, and reducing deaths. Antiviral drugs also have the 25 potential to be used prophylactically, to protect a population in danger of being exposed 1 to the virus. Effective antivirals would also be needed in the future. For example, it is not 2 known whether a new vaccine will provide complete and lasting immunity for everyone, 3 or whether, after enough of the human population gains protective antibodies against 4 the current virus, a mutant SARS-CoV2 virus will emerge that is no longer effectively 5 combated by a current vaccine. However, antivirals are not as effective in ameliorating 6 the disease of patients at later times of a disease after many rounds of virus replication 7 have already occurred, i.e., when patients are hospitalized with severe symptoms. 8

Nevertheless, particularly under the current emergency situation, antivirals should be 9 administered to hospitalized patients because even a relatively small amelioration could 10 save lives. 11

The discovery and development of antivirals is a slow and expensive process. protease is an especially attractive target because effective antivirals directed against 20 proteases of other viruses have been developed and used successfully (9) (10) (11) (12) . 21

Although the optimum inhibitors of the SARS-CoV2 M pro protease for COVID-19 disease 22 are yet to be developed, the potential of using existing drugs which have been approved 23 for at least clinical testing is an extremely attractive first step in dealing with the very 24 urgent need for COVID-19 antivirals.

The structural similarity of the active sites of HCV NS3/4A and SARS-CoV2 M pro 2 proteases is striking and appears to be the result of convergent evolution from different 3 fold topologies to create a similar binding pocket. Koonin and co-workers (36) 4 previously proposed a divergent evolutionary relationship between the cysteine 5 proteases of positive strand RNA viruses (e.g., the 3C proteases of picornaviruses) and 6 chymotrypsin-like serine proteases. Subsequently, based on conserved sequence 7 motifs characteristic of the active-site regions of 3C proteases, they also predicted that 8 identified several FDA-approved drugs as potential inhibitors of M pro , including all of the 1 Table 3 of our manuscript, along with one HCV 2 protease inhibitor, boceprevir. Of these HIV-1 and HCV protease inhibitors, they 3

reported that the HCV NS3/4A protease inhibitor boceprevir had the highest predicted 4 binding affinity, consistent with our results, whereas we found other HCV protease 5 inhibitors that have even higher predicted binding affinity to M pro . Generally speaking, 6 the evolving literature on virtual screening and computational docking supports the 7 hypothesis that available drugs targeting the active site of the HCV NS3/4A protease 8 (and perhaps also of the HIV-1 protease) have potential as quickly mobilized antivirals 9

for COVID-19. This computational study was carried out to evaluate the hypothesis that existing 1 drugs, already FDA-approved or approved for testing in clinical trials, have the potential 2 to bind to the active site of the M pro protease of the SARS-CoV2 virus. We focused 3 primarily on existing drugs that bind to and inhibit the NS3/4A protease of HCV because 4 we found that the active sites of the HCV and SARS-CoV2 proteases are structurally 5 similar, and because there has been success in using protease inhibitors as 6 therapeutics for HepC disease (9, 10). Our computational docking used as a 7

benchmark state the structure of the complex formed between the SARS-CoV2 8 protease and a known inhibitor of this protease, an a-ketoamide molecule denoted as 9

13b (13). The results of our computational docking of HCV protease inhibitors into the 10 active site of the M pro protease of SARS-CoV2 support the hypothesis that several of 11 these HCV inhibitors may effectively bind to and inhibit this protease. However, we do 12

not know yet if any of these drugs are effective for treating COVID-19 disease. Hence, 13 these results provide the rationale for us to test these identified HCV protease inhibitors 14 as inhibitors of the SARS-CoV2 protease activity, and as inhibitors of SARS-CoV2 virus 15

replication. Subsequently these repurposed drugs could be evaluated as COVID-19 16 therapeutics. 13. Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K. and 5

Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of 6 improved alpha-ketoamide inhibitors. Science 2020. 7

https://doi.org/10.1126/science.abb3405 8 9

14. Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. Bottom panels -Details of atomic interactions in the lowest energy AutoDock poses of these HCV protease inhibitors. Hydrogen bonds and hydrophobic interactions between the drug and the enzyme are shown with yellow solid lines and black dashed lines, respectively. Sidechains of catalytic residues His41 and Cys145 are labeled, along with other protein residues that form key interactions with these drugs.

Recent 2 insights into emerging coronaviruses

A pneumonia outbreak associated with a new coronavirus of probable bat 7 origin

A new coronavirus associated with human respiratory disease in China

A SARS-CoV-2-human protein-protein 15 interaction map reveals drug targets and potential drug-repurposing

Potential inhibitors against 2019-nCoV coronavirus M protease 19 from clinically approved medicines

Identification of potential inhibitors of SARS-CoV-2

Main protease via a rapid in-silico drug repurposing approach

Predicting commercially available 27 antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through 28 a drug-target interaction deep learning model

Potentially highly potent drugs 32 for 2019-nCoV

The therapeutic approaches for hepatitis C virus: protease 35 inhibitors and polymerase inhibitors

Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the 40 hepatitis C vrus life cycle

Recent progress in the development of HIV-1 44 protease inhibitors for the treatment of HIV/AIDS

Structure of M(pro) from COVID-19 virus and discovery of its inhibitors

Coronavirus main 14 proteinase (3CLpro) structure: basis for design of anti-SARS drugs

The crystal structures of severe acute respiratory syndrome virus main protease and its 19 complex with an inhibitor

Structure 23 of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra 24 alpha-helical domain

Protein structure comparison by alignment of distance 28 matrices

34 CATH--a hierarchic classification of protein domain structures

43 Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the 44 development of selective chemical tools that differentiate Dengue from Zika and West Nile 45 viruses

alpha-Ketoamides as broad-spectrum inhibitors of Coronavirus and 2 Enterovirus replication: Structure-based design, synthesis, and activity assessment

From SARS to MERS: 10 years of research on highly 6 pathogenic human coronaviruses

AutoDock4 and AutoDockTools4: Automated docking with selective receptor 11 flexibility

Docking screens: right for the right reasons?

Python: a programming language for software integration and 21 development

Automated docking using a Lamarckian genetic algorithm and an empirical binding 25 free energy function

CO;2-B 27 28 30. Delano, W. L. The PyMOL Molecular Graphics System

PLIP: fully 32 automated protein-ligand interaction profiler

A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

Race to find COVID-19 treatments accelerates

Epidemiologic features and clinical course of 47 patients infected with SARS-CoV-2 in Singapore

Thr25, Phe140, Asn142, Glu166, Pro168 Bottom panels -Details of atomic interactions in the lowest energy AutoDock poses of these HCV protease inhibitors. Hydrogen bonds and hydrophobic interactions between the drug and the enzyme are shown with yellow solid lines and black dashed lines, respectively. Sidechains of catalytic residues His41 and Cys145 are labeled, along with other protein residues that form key interactions with these drugs.